Deep knowledge on
small-molecule drugs and
the 100,000 global patents
covering them

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

How are People Using DrugPatentWatch?

DrugPatentWatch Ultimate Plan Preview

Details for Patent: 5,767,251

« Back to Dashboard
Patent 5,767,251 protects OVIDREL, FOLLISTIM, FOLLISTIM AQ, GONAL-F, GONAL-F RFF, GONAL-F RFF REDI-JECT, and LUVERIS, and is included in eight NDAs.

This patent has sixty patent family members in eleven countries.

Summary for Patent: 5,767,251

Title: Recombinant heterodimeric human fertility hormones, and methods, cells, and vectors and DNA for the production thereof
Abstract:Biologically active heterodimeric human fertility hormones composed of two different subunits, each subunit being synthesized in the same cell transformed by at least one cell expression vector having heterologous DNA encoding each subunit with each subunit being controlled by a separate promoter. Preferred human fertility hormones include hCG, hLH and hFSH.
Inventor(s): Reddy; Vermuri B. (Westboro, MA), Hsiung; Nancy (Wellesley, MA), Beck; Anton K. (Grisbeladierbeg, CH), Bernstine; Edward George (Boston, MA)
Assignee: Genzyme Corporation (Cambridge, MA)
Application Number:08/008,233
Patent Claim Types:
see list of patent claims
Patent PDF download available with subscription

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Emd Serono
choriogonadotropin alfa
INJECTABLE;INJECTION021149-001Sep 20, 2000DISCNNo5,767,251<disabled>
Organon Usa Inc
follitropin alfa/beta
INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS020582-001Sep 29, 1997DISCNNo5,767,251<disabled>
Organon Usa Inc
follitropin alfa/beta
INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS020582-002Sep 29, 1997DISCNNo5,767,251<disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 5,767,251

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
4,840,896 Heteropolymeric protein<disabled in preview>
6,455,282 Cells, vectors and methods for producing biologically active TSH<disabled in preview>
5,639,640 DNA encoding the beta subunit of human follide stimulating hormone and expression vectors and cells containing same<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 5,767,251

Country Document Number Publication Date Supplementary Protection Certificate SPC Country SPC Expiration
JapanH11308992Nov 09, 1999
European Patent Office0487512Aug 05, 19982001C/027Belgium<disabled>
Japan2573817Jan 22, 1997
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2016 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn